The Filing Desk

Compugen

CGEN · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CGEN · Last close · November 19, 2026
$1.88

Compugen's revenue rose 161.1% to $73 million in fiscal 2025. Its operating margin was 43.0%, up from −53.4% a year earlier. Free cash flow was $31 million, down 36.7%. The diluted share count rose 4.8%.

COMPUGEN LTD Latest fiscal year ended December 31, 2025 20-F filed March 2, 2026 · 0001178913-26-000663 Updated
Revenue
$73M
161.1%
Operating margin
43.0%
96.5 pts
Net income
$35M
 
Free cash flow
$31M
36.7%
Return on equity
44.8%
68.5 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.

About these figures. Compugen is a foreign company: it files an annual report on Form 20-F, prepared under US accounting standards (US GAAP), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model.

What Compugen does

Compugen is an Israeli drug developer working on cancer immunotherapy: medicines that help the body's immune system attack tumors. It uses its computer platform, called Unigen, to find new drug targets, and then develops antibodies against them. It has no approved products. Its programs are being tested in people, and the only trial it runs itself tests COM701 in women whose ovarian cancer has come back.

It makes money by licensing its targets and drug candidates to larger drug companies, in exchange for upfront fees, milestone payments and royalties. It has two such deals in effect. AstraZeneca is testing rilvegostomig, an antibody built from part of Compugen's COM902 program, in several trials, including late-stage ones. Gilead licensed GS-0321, which Compugen is testing in an early trial. Under the Gilead deal, Compugen can receive up to approximately $758 million more in milestone payments, plus royalties on sales.

Compugen recognized revenue of approximately $72.8 million from its partnerships in 2025, and it made a net profit of approximately $35.3 million that year after losses in earlier years. In 2025 it received $65 million as an additional upfront payment from AstraZeneca. After setbacks for other companies' drugs aimed at the same target, it does not plan new trials of COM902 on its own.

Its biggest risks, as it describes them

  • It has a history of losses and may need to raise more money, which could dilute shareholders.
  • It depends on a few drug candidates and on partners such as AstraZeneca and Gilead to develop and sell them.
  • Clinical trials, its own or those of other companies testing the same targets, may fail to show the drugs are safe and work.
  • Its computer-based way of finding drug targets is not yet proven in the clinic.
  • Conditions in Israel and the Middle East could disrupt its operations.
From Compugen's annual report on Form 20-F, filed March 2, 2026, in our words; the 20-F has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments117112642100
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−1,403.0x−1,310.2x−419.1x−438.0x1,118.8x
Current ratio7.2x7.2x4.4x5.3x6.6x
Quick ratio7.2x7.2x4.4x5.3x6.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40238.3%160.9%204.2%
Altman Z''−7.46−8.87−0.84
Accruals ratio15.9%−54.0%2.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailPassPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomeFailPassFail
Debt fell relative to assets———
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rosePassFailPass
Revenue rose relative to assetsPassFailPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Compugen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CompugenFY25161.1%43.0%43.0%———
CellectisFY2575.8%−45.3%−57.2%———Compare
Bicycle TherapeuticsFY25105.8%−340.4%−347.2%———Compare
Recursion PharmaceuticalsFY2526.9%−867.9%−506.5%−117.2%—4Compare
AbCellera BiologicsFY25160.6%−289.0%−231.7%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1—18—268342873
Revenue growth−92.3%————200.0%25.0%346.1%−16.7%161.1%
Gross profit0—17—256322064
Research and development24293020232931342523
Operating income−33−37−23−29−32−35−35−13−1531
Net income−32−37−23−27−30−34−34−19−1435
Diluted EPS (US$)−0.62−0.72−0.41−0.43−0.37−0.41−0.39−0.21−0.160.38
Diluted shares (millions)51515564808487889094
Cash flow
Cash from operations−20−31−13−28−28−23−34−365032
Capital expenditure3000000000
Free cash flow−22−31−13−28−28−23−35−364931
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation3322344432
Balance sheet at fiscal year end
Cash and short-term investments60294543124117112642100
Debt incl. finance leases——————————
Total assets7139535413813294121115157
Total liabilities891615182616566054
Shareholders' equity64293738120107786655103
Margins and ratios
Gross margin68.7%—94.2%—97.0%88.7%87.0%94.0%71.5%87.3%
Operating margin−4,576.3%—−130.5%—−1,574.8%−584.6%−471.6%−38.8%−53.4%43.0%
Net margin−4,425.0%—−127.0%—−1,484.9%−570.0%−449.2%−56.0%−51.1%48.6%
Free cash flow margin−3,148.6%—−75.6%—−1,424.3%−383.1%−461.2%−107.8%177.6%43.0%
Rule of 40 (growth + FCF margin)−3,240.9%————−183.1%−436.2%238.3%160.9%204.2%
Return on capital——————————
Return on equity−41.1%−79.9%−67.9%−72.3%−37.6%−30.2%−36.5%−26.2%−23.6%44.8%
Return on assets−37.0%−67.5%−49.2%−51.1%−30.9%−25.3%−29.8%−17.4%−12.0%26.0%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Compugen's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Compugen.